|1.||Sun, Daekyu: 3 articles (01/2013 - 08/2004)|
|2.||Gates, Kent S: 2 articles (01/2013 - 05/2008)|
|3.||Rajapakse, Anuruddha: 1 article (01/2013)|
|4.||Keerthi, Kripa: 1 article (01/2013)|
|5.||Gates, Kent: 1 article (01/2010)|
|6.||Viswesh, Velliyur: 1 article (01/2010)|
|7.||Sivaramakrishnan, Santhosh: 1 article (05/2008)|
|8.||Vecsernyés, Miklós: 1 article (09/2006)|
|9.||Fenyvesi, Ferenc: 1 article (09/2006)|
|10.||Herczegh, Pal: 1 article (09/2006)|
08/01/2004 - "Here, we evaluated the effects of leinamycin in the human pancreatic carcinoma cell line MiaPaCa. "
01/01/2010 - "In the present study, we have determined the endogenous amount of AP sites and DNA strand breaks in genomic DNA and the amount of oxidative stress in a human pancreatic carcinoma cell line, MiaPaCa, treated with leinamycin by utilizing the aldehyde-reactive probe assay, the comet assay, and fluorescent probes, respectively. "
01/01/2013 - "Leinamycin (1) is a Streptomyces-derived natural product that displays nanomolar IC(50) values against human cancer cell lines. "
01/01/2010 - "Leinamycin is a structurally novel Streptomyces-derived natural product that displays very potent activity against various human cancer cell lines (IC(50) values in the low nanomolar range). "
01/01/2010 - "Characterization of DNA damage induced by a natural product antitumor antibiotic leinamycin in human cancer cells."
09/07/2006 - "All of these analogues of leinamycin showed cytotoxic activity against HeLa3 tumor cells. "
10/01/1995 - "The percentage of tumor area 6 weeks after therapy was 30.8% of the metropeutic size in the Group DC+CT, 46.8% in the Group DC, 107% in the Group CT and 267% in the control (Group DC+CT vs the other groups: p < 0.05). "
|3.||Pancreatic Neoplasms (Pancreatic Cancer)
|1.||Fluorescent Dyes (Fluorescent Probes)
|2.||DNA (Deoxyribonucleic Acid)